Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy
Lung cancer is the most frequently diagnosed cancer type and the leading cause of cancer-related deaths worldwide. According to the last GLOBOCAN estimate of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), lung cancer accounted for approximately 13%...
Main Author: | Tiziana Vavalà |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2018-06-01
|
Series: | European Medical Journal |
Subjects: | |
Online Access: | https://www.emjreviews.com/oncology/article/management-of-non-small-cell-lung-cancer-the-era-of-immunotherapy/ |
Similar Items
-
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
by: Niki Karachaliou, et al.
Published: (2015-06-01) -
Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01) -
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
by: Li-Chung Chiu, et al.
Published: (2021-06-01) -
Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
by: Maria A Papadaki, et al.
Published: (2020-06-01) -
New targeted treatments for non-small-cell lung cancer – role of nivolumab
by: Zago G, et al.
Published: (2016-08-01)